# Paratek Pharmaceuticals Inc. (PRTK)

Source: https://www.quantisnow.com/company/PRTK
Generated: 2026-11-06T01:08:57.950Z

- Ticker: PRTK
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: paratekpharma.com

## About

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

## Latest PRTK news and filings

- 2023-10-02 11:33 UTC [SEC Form 15-12G filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-paratek-pharmaceuticals-inc-4996175)
- 2023-09-26 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-paratek-pharmaceuticals-inc-4987107)
- 2023-09-21 17:24 UTC [SEC Form 4] [SEC Form 4: Baylor-Henry Minnie returned 59,200 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-baylor-henry-minnie-returned-59200-shares-to-the-4982526)
- 2023-09-21 17:24 UTC [SEC Form 4] [SEC Form 4: Hoffmann Rolf K returned 84,000 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-hoffmann-rolf-k-returned-84000-shares-to-4982525)
- 2023-09-21 17:23 UTC [SEC Form 4] [SEC Form 4: Brenner Randall B. returned 415,209 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-brenner-randall-b-returned-415209-shares-to-4982524)
- 2023-09-21 17:21 UTC [SEC Form 4] [SEC Form 4: Peterson Kristine returned 79,000 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-peterson-kristine-returned-79000-shares-to-the-4982523)
- 2023-09-21 17:21 UTC [SEC Form 4] [SEC Form 4: Stein Jeffrey returned 68,625 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-stein-jeffrey-returned-68625-shares-to-the-4982522)
- 2023-09-21 17:20 UTC [SEC Form 4] [SEC Form 4: Haskel William M. returned 447,024 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-haskel-william-m-returned-447024-shares-to-4982520)
- 2023-09-21 17:18 UTC [SEC Form 4] [SEC Form 4: Bigham Michael exercised 23,255 shares at a strike of $4.30 and returned 1,358,032 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-bigham-michael-exercised-23255-shares-at-a-4982518)
- 2023-09-21 17:17 UTC [SEC Form 4] [SEC Form 4: Franson Timothy R returned 72,000 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-franson-timothy-r-returned-72000-shares-to-4982517)
- 2023-09-21 17:17 UTC [SEC Form 4] [SEC Form 4: Woodrow Adam returned 749,034 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-woodrow-adam-returned-749034-shares-to-the-4982512)
- 2023-09-21 17:15 UTC [SEC Form 4] [SEC Form 4: Loh Evan returned 1,327,981 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-loh-evan-returned-1327981-shares-to-the-4982510)
- 2023-09-21 17:13 UTC [SEC Form 4] [SEC Form 4: Dietz Thomas John returned 69,250 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-dietz-thomas-john-returned-69250-shares-to-4982506)
- 2023-09-21 17:12 UTC [SEC Form 4] [SEC Form 4: Radie Robert S returned 73,000 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-radie-robert-s-returned-73000-shares-to-4982505)
- 2023-09-21 14:59 UTC [SEC Form SC 13E3/A filed by Paratek Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13e3a-filed-by-paratek-pharmaceuticals-inc-amendment-4982274)
- 2023-09-21 14:42 UTC [SEC Form POS AM filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-paratek-pharmaceuticals-inc-4982238)
- 2023-09-21 14:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982233)
- 2023-09-21 14:37 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982228)
- 2023-09-21 14:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982222)
- 2023-09-21 14:30 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982217)
- 2023-09-21 14:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982213)
- 2023-09-21 14:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982209)
- 2023-09-21 14:24 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982205)
- 2023-09-21 14:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982201)
- 2023-09-21 14:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982195)
- 2023-09-21 14:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982192)
- 2023-09-21 14:14 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982190)
- 2023-09-21 14:12 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982183)
- 2023-09-21 14:10 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982180)
- 2023-09-21 14:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982177)
- 2023-09-21 14:05 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982169)
- 2023-09-21 14:03 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982166)
- 2023-09-21 14:00 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982161)
- 2023-09-21 13:57 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982143)
- 2023-09-21 13:54 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982138)
- 2023-09-21 13:51 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982136)
- 2023-09-21 13:49 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982132)
- 2023-09-21 13:46 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982126)
- 2023-09-21 13:44 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Paratek Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-paratek-pharmaceuticals-inc-4982120)
- 2023-09-21 13:07 UTC [SEC Form 8-K] [Paratek Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/paratek-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-4982043)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PRTK
- Earnings history: https://www.quantisnow.com/earnings/PRTK
- Dividend history: https://www.quantisnow.com/dividends/PRTK
- Insider transactions: https://www.quantisnow.com/insiders/PRTK
- Options chain: https://www.quantisnow.com/options/PRTK
- SEC 8-K filings only: https://www.quantisnow.com/company/PRTK/8-k
- RSS and alerts for PRTK: https://www.quantisnow.com/docs/rss-feeds.md